Hantavirus cases spark brief surge in pharma and biotech stocks – here’s why trading is so volatile
Summary:
A hantavirus outbreak on a cruise ship sparked a brief surge in biotech stocks like Moderna and Inovio as investors weighed vaccine potential. However, analysts maintain that the low-incidence virus offers no meaningful revenue opportunity, labeling the volatility sentiment-driven.
Cancer, immunology startups lead latest wave of stealth exits
Summary:
Biotech startups focused on oncology and immunology are leading a new wave of stealth exits, raising $500 million. Notable newcomers include Beeline Medicines, targeting lupus, and Slate Medicines, which is developing a subcutaneous anti-PACAP monoclonal antibody for migraine prevention.
Biotech has a new company model: A small team, a big check and a few Chinese assets
Summary:
Biotech’s “NewCo” model is surging, characterized by small teams using large capital infusions to in-license clinical-stage assets from China. This strategy bypasses early-stage discovery to secure faster returns, shifting investor focus toward high-value, trial-ready treatments for obesity and autoimmune diseases.
LenioBio, Twist Bioscience aim to speed wet-lab checks for AI-designed proteins
Summary:
LenioBio and Twist Bioscience have partnered to accelerate AI-led drug discovery by integrating cell-free protein expression with automated DNA manufacturing. This collaboration enables 24-hour wet-lab validation of computationally designed proteins, rapidly feeding experimental data back into models to optimize development.
European regulators greenlight first clinical test of GLP-1 gene therapy
Summary:
European regulators have cleared Fractyl Health to begin the first clinical trial of a GLP-1 gene therapy for type 2 diabetes. Using an AAV vector, the “one-and-done” treatment aims to provide permanent glucose control and superior tolerability compared to chronic injections.
